Skip to main content
OpenTrials
Completed

NCT Number: NCT01500148

St. Jude Medical Percutaneous Mitral Valve Repair Study

The purpose of this proof-of-concept study is to assess the relative safety and feasibility of the SJM Percutaneous Mitral Valve Repair (PMVr) Device.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Papworth Hospital

Cambridge, United Kingdom

About this study

Subjects will be followed-up through 6 weeks post implantation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has symptomatic or asymptomatic moderate (2+) or severe (3-4+) mitral regurgitation.
  • Subject has an ejection fraction (EF) ≥ 30%.
  • Subject is of legal age (≥18 years old).
  • Subject is planned to undergo surgical repair or replacement of the mitral valve for symptomatic or asymptomatic posterior leaflet mitral prolapse.

Exclusion criteria

  • Subject requires a complex mitral valve repair or has isolated anterior prolapse.
  • Subject has mitral valve stenosis in which the annulus opening is <10mm. Subject has valve disease other than mitral which requires surgical intervention.
  • Subject requires a concomitant procedure.
  • Subject has a pre-existing prosthetic valve in any position.
  • Subject had stenting or PCI within 6 months before the planned procedure, or is anticipated to require stenting or PCI within 6 months post-procedure.
  • Subject has calcification of the mitral leaflets or annulus which in the medical opinion of the surgical investigator would limit repair and /or implantation of the investigational device.
  • Subject has renal insufficiency or is on chronic dialysis.
  • Subject has had a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months.
  • Subject has a history of endocarditis or has active endocarditis.
  • Subject has a history of autoimmune disease.
  • Subject has significant known carotid artery disease.
  • Subject has an aorto-mitral angle of <110 degrees.
  • Subject has hypertrophic obstructive cardiomyopathy (HOCM's Disease).

Treatment and study plan

PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)

Device

A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.

Primary outcomes

  1. Device and Procedural Success

    Time frame: During the investigational procedure

    The primary objective is to evaluate the technical feasibility and acute device deployment characteristics of the SJM PMVr Device.

    Technical feasibility and deployment characteristics will be defined as:

    • The ability of the delivery system to access the mitral valve
    • The ability of the device to capture mitral valve (MV) leaflet tissue
    • Ability to plicate MV leaflet tissue
    • The clip is able to be deployed in MV leaflet tissue
    • The delivery system is able to be removed.

Secondary outcomes

  1. Quantification of SAEs reported that are unique to the investigational procedure

    Time frame: Through 6 weeks post-implantation

    The secondary objective is to evaluate safety of the SJM PMVr device by summarizing SAEs unique to accessing the valve, placing the clip, and removing the delivery system.

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

Clinical Assessment of the St. Jude Medical (SJM) Percutaneous Mitral Valve Repair (PMVr) Device Concept

Acronym: SJM PMVr

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Dec 28, 2011
Registry last updated
Feb 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.